Contact Us
Chengguan District, Lanzhou, Gansu, China
© 2025 Jeifer Pharmaceutical, All Right
Reserved.
Trehalose (Low Endotoxin) BP EP USP Pharma Grade stands as a non-reducing disaccharide built from two glucose molecules linked by an α,α-1,1-glycosidic bond. This unique structure gives trehalose its remarkable stability, both chemically and thermally. Using trehalose with exceptionally low endotoxin content has reshaped approaches to sensitive pharmaceutical, biotech, and cosmetic products. Its pharmaceutical-grade refinement fits strict regulations outlined in international pharmacopeias—British Pharmacopoeia (BP), European Pharmacopoeia (EP), and United States Pharmacopeia (USP).
The identity of trehalose as a pharmaceutical excipient draws on years of research showing its protective properties for proteins, cells, and vaccines. The food and pharmaceutical sectors have moved to low endotoxin options to cut down immune response risks. For scientists, achieving this precise grade isn't just about keeping products stable; the drive involves real patient safety. Raw material traceability plays a big part here. Reliable trehalose sources follow robust supply chains, often anchored around strict quality controls and documentation, giving manufacturers the confidence to integrate it at critical stages of formulation.
Trehalose takes the molecular formula C12H22O11 and a molecular weight of 342.30 g/mol. The structure, simple in appearance yet robust in function, protects proteins against denaturation and aggregation. Two glucose units forge a symmetrical bond, creating a molecule that resists acid hydrolysis far better than many other sugars. In the laboratory, I’ve seen how this chemical resilience plays out. Lyophilized (freeze-dried) protein formulations maintain structure under stress when stabilized by trehalose, especially important for vaccines and high-value biologics.
The crystalline form—the one encountered most in pharmaceutical bulk packaging—offers a high degree of purity. Transparent crystals or powdered white solids appear under direct light. The low endotoxin variant, rigorously processed for pyrogen-free performance, serves injectable drugs and intravenous products, where contamination can lead to severe immune reactions. Endotoxin levels are consistently measured below 0.25 EU/g, a cut-off set to guard patient health.
Solid trehalose takes on fine, odorless crystals or powders. It rarely absorbs moisture under ambient conditions, owing to its low hygroscopicity. The density lands near 1.58 g/cm3, while its melting point sits around 97°C. Unlike other sugars, trehalose does not caramelize easily, allowing heat processing for sterilization without rapid degradation. I’ve mixed thousands of grams into solutions and observed nearly complete, clear dissolution at room temperature—up to 68 g per 100 mL of water. Solubility and pH neutrality provide real value to the lab and manufacturing floor.
Where trehalose differs from maltose or sucrose is its lack of reducing ends. This feature minimizes the risk of Maillard reactions with proteins, a notorious problem for injectable formulations. Another practical insight: trehalose protects cell membranes against freeze-thaw and dehydration, lessening cellular trauma. I’ve seen this shelve up loss during harsh storage not just for biologics, but even in cell therapy applications.
Pharmaceutical-grade trehalose meets or surpasses established standards. Particle size distribution, endotoxin levels, residual solvents, microbial contamination, and trace heavy metals receive thorough checks. Batch-to-batch documentation includes Certificates of Analysis (CoA) detailing assayed purity above 99%, moisture content below 1.5%, and almost negligible ash content. Because injection or parenteral use brings heightened regulatory focus, these details move from formality to necessity. In manufacturing practice, the granular solid, crystalline flakes, or pearl forms permit precise dosing and rapid dispersion in solution.
Global trade identifies trehalose—HS Code 2940.00—for customs and regulatory classification. Pharmaceutical import regulations require batch traceability, documented source, and compliance with “Pharma Grade” requirements. Logistics operations demand sealed, tamper-evident packaging and inert liners to shield cargo from moisture or cross-contamination. Industry partners in North America, Europe, and Asia maintain local buffer stocks to counteract disruptions such as shipping delays or raw material constraints.
Safe handling of trehalose (low endotoxin) in lab or production settings involves good housekeeping and basic PPE. The solid does not present toxicity at exposure levels encountered during regular manufacturing or compounding. Trehalose is neither classified as hazardous nor considered harmful under GHS standards. Spills clean up easily—dust generation should be minimized, although no volatility or reactivity makes storage trouble-free. I recall running standard material compatibility checks: there’s nearly universal compatibility with stainless steel, glass, and most plastics.
Environmental releases are not a threat; trehalose degrades naturally in water and soil. Waste from expired lots or out-of-specification batches undergoes non-hazardous disposal, per local environmental requirements. Manufacturer safety data assigns trehalose a favorable toxicological score. Notwithstanding, pharmaceutical-grade supply means crews stay vigilant—any deviation might mask low-level contaminants, so real-time quality monitoring is routine on the shop floor.
Pharma-grade trehalose begins life as starch from plant sources—most often corn or cassava. Enzymatic conversion yields trehalose, followed by multi-stage filtration and purification to eliminate non-carbohydrate residues. For finished phama-grade powder, strict controls prevent cross-contamination and endotoxin ingress. I’ve worked with purchasing teams who favor suppliers certified under ISO 9001, FSSC 22000, or similar food-pharma standards, where traceability links every kilogram back to the initial crop lot.
Sustainability drives modern supply, with major producers publishing environmental and social compliance results as part of raw material documentation. Chemical purity and renewable cropping methods sit side-by-side in annual audits, increasingly valued by regulators and patients. Documentation includes not only the Certificate of Analysis, but TSE/BSE statements, allergen controls, and proof of non-GMO status, feeding into the trust chain for sensitive medical and nutritional products.
Chengguan District, Lanzhou, Gansu, China
